Neon Therapeutics, Inc. logo

Neon Therapeutics, Inc.

Neon Therapeutics, is an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer.

Neons lead candidate NEO-PV-01, a personalized neoantigen vaccine is build on the initial clinical trials developed collaboratively by the Broad Institute and Dana-Farber Cancer Institute.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”NTGN” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://neontherapeutics.com
Founded2015
Disease Focus
Development Stage
STOCK CODENASDAQ: NTGN
Address
40 Erie Street, Suite 110,MA 2139
Cambridge
United States
Email
Contact Number
+1 617-337-4701

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/neon-therapeutics” connections=”true” suffix=””]

In Dec 2017, Neon signed clinical research collaborative with Merck (known as MSD) to evaluate Neon Therapeutics proprietary personal neoantigen vaccine, NEO-PV-01, in combination with Mercks anti-PD-1 therapy, KEYTRUDAë (pembrolizumab), along with chemotherapy. Additional details were not disclosed.

In July 2017, CRISPR Therapeutics (NASDAQ:CRSP) and Neon signed a research collaboration to explore the combination of each companys proprietary technologies to develop novel T cell therapies.

In July 2017, Neon signed clinical research collaborative with Apexigen, Inc., to evaluate Neon Therapeutics proprietary personal neoantigen vaccine, NEO-PV-01, in combination with Apexigens CD40 agonist antibody, APX005M, for the treatment of patients with metastatic melanoma.

Neon Therapeutics signs non-exclusive research collaboration with Vedantra Pharmaceuticals to Develop Novel Cancer Immunotherapies combining Vedantras cutting-edge, lymph node targeting amphiphile technology with Neons innovative capabilities in neoantigen vaccine research.

In Feb 2016, Neon signed collaborative research agreement with Netherlands Cancer Institutes (NKI) Antoni van Leeuwenhoek Hospital and Amsterdam Biotherapeutics Unit to combine complementary capabilities to develop personalized T cell therapies.

In Feb 2016, Neon signed collaborative research agreement with Sanquin Blood Supply Foundation for its technology to be utilized across Neon Therapeutics pipeline. The technology utilizes ultraviolet light-based exchange for fast and simple generation of large series of peptide-MHC complexes for in vitro and ex vivo detection and characterization of antigen-specific T cells.

In Dec 2015, Neon Therapeutics, singed a clinical trial collaboration with Bristol-Myers Squibb to evaluate the combination of Neon Therapeutics proprietary personalized neoantigen vaccine, NEO-PV-01, and Opdivoë (nivolumab), a PD-1 immune checkpoint inhibitor. Additional details of the collaboration were not disclosed.

In June 2018, Neon Therapeutics raised $100 Mn through IPO eries A financing from Third Rock Ventures, Clal Biotechnology Industries and Access Industries.

In Dec 2017, Neon raised an additional $36 Mn extension to its Series B financing which, combined with $70 Mn announced in January 2017, brings the total raised during this Series B crossover round to $106 Mn. Participants included Fidelity Management & Research Company, Partner Fund Management, Access Industries, Wellington Management, Pharmstandard International, Arrowmark Partners, Nextech Invest, Hillhouse Capital Group and Casdin Capital.

In Oct 2015, Neon Therapeutics raised $55 Mn in Series A financing from Third Rock Ventures, Clal Biotechnology Industries and Access Industries.